Switching from Donepezil to Rivastigmine Patch for Tremor Side Effects
Yes, switching from donepezil to the rivastigmine transdermal patch (Exelon Patch) is appropriate and well-supported when tremor or other movement disorders develop, as patients who do not respond to or cannot tolerate one cholinesterase inhibitor may respond to another 1.
Clinical Rationale for Switching
The guideline evidence explicitly states that cholinesterase inhibitors should be discontinued if side effects develop and do not resolve, and importantly, patients who do not respond to one cholinesterase inhibitor may respond to another 1. This provides clear support for switching medications when tremor becomes problematic.
Movement Disorders with Cholinesterase Inhibitors
Tremor and other movement disorders are recognized adverse effects of cholinesterase inhibitors, particularly donepezil. Recent systematic review data shows that donepezil accounts for 62 out of 92 reported cases of movement disorders (67.4%), while rivastigmine accounts for only 15 cases (16.3%) 2. The movement disorders associated with these medications include:
- Parkinsonism (31 cases)
- Pisa syndrome (33 cases)
- Myoclonus (11 cases)
- Dystonia (10 cases)
Importantly, approximately 86.3% of patients fully recovered after discontinuation or switching of the offending agent 2. This strongly supports switching strategies when movement disorders emerge.
How to Execute the Switch
Direct Switch Protocol (Recommended)
Apply the first Exelon Patch 4.6 mg/24 hours on the day following the last donepezil dose 3. This immediate switch strategy has been validated in multiple clinical trials 4, 5.
The evidence shows:
- Both immediate and delayed (7-day withdrawal) switching strategies were safe and well-tolerated 4, 5
- Discontinuation rates were similar between immediate and delayed switch groups 4, 5
- Gastrointestinal adverse events were low: 3.8% in immediate switch vs 0.8% in delayed switch 5
- No patients discontinued due to nausea or vomiting 5
Titration Schedule
- Start with Exelon Patch 4.6 mg/24 hours 3
- After minimum 4 weeks, if well-tolerated, increase to 9.5 mg/24 hours (the recommended effective maintenance dose) 3
- Apply to clean, dry, hairless skin on upper/lower back (preferred) or upper arm/chest 3
- Rotate application sites daily to prevent skin irritation 3
Advantages of the Transdermal Patch
The rivastigmine patch offers significant tolerability advantages over oral formulations:
Gastrointestinal side effects are dramatically reduced compared to oral rivastigmine:
- Nausea: 3.8% (patch) vs 32.9% (oral capsules) 6
- Vomiting: 4.2% (patch) vs 24.1% (oral capsules) 6
- Discontinuation due to adverse events: 14.6% (patch) vs 19.3% (oral capsules) 6
The patch provides steady drug delivery over 24 hours with less fluctuation, which contributes to improved tolerability while maintaining efficacy comparable to the highest oral dose 7.
Important Caveats
Bradycardia Risk
Use appropriate clinical judgment for patients with existing bradycardia or those receiving beta blockers 5. One study found asymptomatic bradycardia was more common with immediate switching (2.3% vs 0%), though these patients had pre-existing cardiac comorbidities 5.
Application Site Reactions
Application site reactions occur but are generally mild and manageable through daily site rotation 6, 5. Discontinuation due to skin reactions was low at 2.3% 5.
Low Body Weight
Patients weighing less than 50 kg may experience more adverse events and require particular caution when titrating above 9.5 mg/24 hours 3.
Worsening of Parkinsonism
While rivastigmine appears to cause fewer movement disorders than donepezil overall 2, like all cholinomimetics, rivastigmine may exacerbate extrapyramidal symptoms, particularly tremor, in patients with Parkinson's disease dementia 3, 8. However, given that the tremor is attributed to donepezil, switching is still reasonable.
Monitoring After Switch
- Assess response within 3 months - beneficial effects should be observed within this timeframe 9
- Monitor for resolution of tremor - most movement disorders resolve after discontinuation of the offending agent 8, 2
- Watch for application site reactions and rotate patch locations daily 3
- Evaluate cognitive, functional, and behavioral outcomes to ensure no deterioration occurs 4
Expected Outcomes
Studies demonstrate that the majority of patients can be safely switched from donepezil to rivastigmine patches without significant deterioration in cognition, behavior, or global functioning 4. Over half of patients in switching studies preferred the transdermal patch to oral tablets 4.